<p>Relay Therapeutics, Inc.（纳斯达克代码：RLAY - 获取免费报告）在周三收到了异常的期权交易。投资者购买了 5,007 份该股票的看跌期权。这比典型的每日 744 份看跌期权的交易量增加了约 573%。</p>
<p>获取 <strong>Relay Therapeutics</strong> 的提醒：</p>
<h2>Relay Therapeutics 价格表现</h2>
<ul>
<li>解锁医疗保健领域的人工智能投资机会</li>
</ul>
<p>周三，纳斯达克 RLAY 上涨 0.67 美元，达到 12.74 美元。该股票的交易量为 1,505,274 股，而其平均交易量为 2,913,018 股。该公司的 50 日移动平均价格为 12.56 美元，200 日移动平均价格为 9.62 美元。该股票的市值为 24.4 亿美元，市盈率为-8.09，贝塔值为 1.74。Relay Therapeutics 的 52 周低点为 2.75 美元，52 周高点为 17.32 美元。</p>
<p>Relay Therapeutics（纳斯达克代码：RLAY - 获取免费报告）最近在 5 月 5 日（星期二）发布了季度财报。该公司报告每股收益为-0.41 美元，低于分析师一致预期的-0.35 美元，差距为 0.06 美元。该公司在本季度的收入为 300 万美元，而分析师预期为 558 万美元。整体来看，卖方分析师预计 Relay Therapeutics 在当前年度的每股收益为-1.6。</p>
<h2>影响 Relay Therapeutics 的关键故事</h2>
<p>以下是本周影响 Relay Therapeutics 的关键新闻：</p>
<ul>
<li>积极情绪：Relay 表示，zovegalisib 在罕见疾病环境中产生了早期肿瘤/病变缩小和症状改善，强化了该药物的差异化和商业潜力。文章标题</li>
<li>积极情绪：该公司在成人和青少年中开启了扩展队列，显示出临床项目的势头和更广泛发展的路径。文章标题</li>
<li>积极情绪：Raymond James 上调了 RLAY 的目标价，反映出华尔街对新数据后管道的信心提升。文章标题</li>
<li>中性情绪：Relay 还宣布拟进行 1.75 亿美元的普通股发行，这增加了现金资源，但可能会稀释现有股东的股份。文章标题</li>
<li>消极情绪：新的股权融资可能在短期内对股票施加压力，因为这增加了供应，并暗示管理层希望在近期上涨后增强资产负债表。文章标题</li>
</ul>
<h2>华尔街分析师预测增长</h2>
<p>多家研究分析师对 RLAY 股票发表了评论。瑞银集团在周二的研究报告中将 Relay Therapeutics 的目标价设定为 26.00 美元。JonesTrading 在 4 月 14 日（星期二）开始覆盖 Relay Therapeutics 的股票。他们对该股票设定了 “持有” 评级和 18.00 美元的目标价。Oppenheimer 在 4 月 28 日（星期二）的研究报告中将 Relay Therapeutics 的目标价从 14.00 美元上调至 18.00 美元，并给予该股票 “跑赢大盘” 评级。华尔街 Zen 在 5 月 9 日（星期六）的报告中将 Relay Therapeutics 的评级从 “持有” 下调至 “卖出”。最后，Guggenheim 在 3 月 13 日（星期五）将 Relay Therapeutics 的目标价从 15.00 美元上调至 22.00 美元，并在报告中给予该公司 “买入” 评级。一位投资分析师对该股票给予了强烈买入评级，八位分析师给予买入评级，一位分析师给予持有评级，一位分析师给予卖出评级。根据 MarketBeat 的数据，Relay Therapeutics 的共识评级为 “适度买入”，共识目标价为 22.60 美元。</p>
<p><strong>查看我们关于 Relay Therapeutics 的最新报告</strong></p>
<h2>Relay Therapeutics 的内部活动</h2>
<p>在相关消息中，首席财务官 Thomas Catinazzo 于 5 月 14 日（星期四）出售了 17,717 股 Relay Therapeutics 股票。该股票以平均价格 12.86 美元出售，总价值为 227,840.62 美元。出售完成后，首席财务官直接持有该公司 195,178 股股票，价值为 2,509,989.08 美元。此次交易使其持股减少了 8.32%。该交易已在与美国证券交易委员会的法律文件中披露，相关文件可通过美国证券交易委员会网站获取。在过去 90 天内，公司内部人士共出售了 40,449 股股票，价值 532,889 美元。公司内部人士持有公司股票的 5.04%。</p>
<h2>对 Relay Therapeutics 的对冲基金看法</h2>
<p>几家对冲基金和其他机构投资者最近修改了对 RLAY 的持股。Torren Management LLC 在第四季度购买了 Relay Therapeutics 的新股份，价值约 30,000 美元。KBC Group NV 在第一季度收购了 Relay Therapeutics 的新股份，价值 34,000 美元。Smartleaf Asset Management LLC 在第四季度将其在 Relay Therapeutics 的股份增加了 288.6%。Smartleaf Asset Management LLC 现在拥有该公司 4,426 股股票，价值 37,000 美元，此前在此期间又购买了 3,287 股。Caitong International Asset Management Co. Ltd 在第四季度购买了 Relay Therapeutics 的新股份，价值 46,000 美元。最后，Captrust Financial Advisors 在第二季度购买了 Relay Therapeutics 的新股份，价值 49,000 美元。96.98% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Relay Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Relay Therapeutics, Inc 是一家临床阶段的生物技术公司，专注于发现和开发精准治疗肿瘤的疗法。公司总部位于马萨诸塞州剑桥，成立于 2016 年，旨在利用综合科学平台针对动态蛋白质运动。Relay Therapeutics 利用计算建模、结构生物学和实验验证来识别能够调节与疾病相关的蛋白质行为的小分子药物候选者。</p>
<p>公司的核心业务活动集中在其专有的药物发现引擎上，该引擎结合了高性能计算（包括分子动力学模拟）与先进的实验技术，如冷冻电子显微镜和生物物理筛选。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比 Relay Therapeutics 更好的股票</li>
<li>特斯拉结束 Model S 和 X 时代，全力押注未来</li>
<li>为什么 AST SpaceMobile 是 AT&amp;T、T-Mobile 和 Verizon 联合企业的更大赢家</li>
<li>Strategy Inc. 在市场恐慌中购买比特币并关注分红</li>
<li>Vertical Aerospace：飞行前检查指向突破</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Relay Therapeutics 吗？</h2>
<p>在考虑 Relay Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Relay Therapeutics 并不在名单上。</p>
<p>虽然 Relay Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RLAY

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

标普生物技术 3 倍做多 - Direxion

基因改革 ETF - ARK

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Relay Therapeutics (NASDAQ: RLAY) 的期权交易显著增加，购买了 5,007 份看跌期权，较日均交易量上涨 573%。该股票交易价格上涨至 $12.74，市值为 24.4 亿美元。分析师的看法不一，价格目标范围在 $18 到 $26 之间。公司还宣布了一项拟议的 1.75 亿美元普通股发行，这可能会稀释现有股东的权益</p>

<p>Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) was the recipient of some unusual options trading on Wednesday. Investors bought 5,007 put options on the stock. This represents an increase of approximately 573% compared to the typical daily volume of 744 put options.</p>
<div class="lb-trans"><p>Relay Therapeutics, Inc.（纳斯达克代码：RLAY - 获取免费报告）在周三收到了异常的期权交易。投资者购买了 5,007 份该股票的看跌期权。这比典型的每日 744 份看跌期权的交易量增加了约 573%。</p>
</div><p>Get <strong>Relay Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Relay Therapeutics</strong> 的提醒：</p>
</div><h2>Relay Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Relay Therapeutics 价格表现</h2>
</div><ul>
<li>Unlocking AI investment opportunities in healthcare</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁医疗保健领域的人工智能投资机会</li>
</ul>
</div><p>NASDAQ RLAY traded up $0.67 on Wednesday, hitting $12.74. The stock had a trading volume of 1,505,274 shares, compared to its average volume of 2,913,018. The business's fifty day moving average price is $12.56 and its 200 day moving average price is $9.62. The stock has a market cap of $2.44 billion, a price-to-earnings ratio of -8.09 and a beta of 1.74. Relay Therapeutics has a 52-week low of $2.75 and a 52-week high of $17.32.</p>
<div class="lb-trans"><p>周三，纳斯达克 RLAY 上涨 0.67 美元，达到 12.74 美元。该股票的交易量为 1,505,274 股，而其平均交易量为 2,913,018 股。该公司的 50 日移动平均价格为 12.56 美元，200 日移动平均价格为 9.62 美元。该股票的市值为 24.4 亿美元，市盈率为-8.09，贝塔值为 1.74。Relay Therapeutics 的 52 周低点为 2.75 美元，52 周高点为 17.32 美元。</p>
</div><p>Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). The firm had revenue of $3.00 million during the quarter, compared to analysts' expectations of $5.58 million. As a group, sell-side analysts anticipate that Relay Therapeutics will post -1.6 EPS for the current year.</p>
<div class="lb-trans"><p>Relay Therapeutics（纳斯达克代码：RLAY - 获取免费报告）最近在 5 月 5 日（星期二）发布了季度财报。该公司报告每股收益为-0.41 美元，低于分析师一致预期的-0.35 美元，差距为 0.06 美元。该公司在本季度的收入为 300 万美元，而分析师预期为 558 万美元。整体来看，卖方分析师预计 Relay Therapeutics 在当前年度的每股收益为-1.6。</p>
</div><h2>Key Stories Impacting Relay Therapeutics</h2>
<div class="lb-trans"><h2>影响 Relay Therapeutics 的关键故事</h2>
</div><p>Here are the key news stories impacting Relay Therapeutics this week:</p>
<div class="lb-trans"><p>以下是本周影响 Relay Therapeutics 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Relay said zovegalisib produced early tumor/lesion shrinkage and symptom improvement in a rare-disease setting, reinforcing the drug’s differentiation and commercial potential. Article Title</li>
<li>Positive Sentiment: The company opened expansion cohorts in adults and adolescents, signaling momentum in the clinical program and a path toward broader development. Article Title</li>
<li>Positive Sentiment: Raymond James raised its price target on RLAY, reflecting improved Wall Street confidence in the pipeline after the new data. Article Title</li>
<li>Neutral Sentiment: Relay also announced a proposed $175 million common-stock offering, which increases cash resources but can dilute existing shareholders. Article Title</li>
<li>Negative Sentiment: The new equity raise may pressure the stock in the near term because it adds supply and suggests management wants to bolster the balance sheet after the recent run-up. Article Title</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Relay 表示，zovegalisib 在罕见疾病环境中产生了早期肿瘤/病变缩小和症状改善，强化了该药物的差异化和商业潜力。文章标题</li>
<li>积极情绪：该公司在成人和青少年中开启了扩展队列，显示出临床项目的势头和更广泛发展的路径。文章标题</li>
<li>积极情绪：Raymond James 上调了 RLAY 的目标价，反映出华尔街对新数据后管道的信心提升。文章标题</li>
<li>中性情绪：Relay 还宣布拟进行 1.75 亿美元的普通股发行，这增加了现金资源，但可能会稀释现有股东的股份。文章标题</li>
<li>消极情绪：新的股权融资可能在短期内对股票施加压力，因为这增加了供应，并暗示管理层希望在近期上涨后增强资产负债表。文章标题</li>
</ul>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of research analysts have commented on RLAY shares. UBS Group set a $26.00 target price on shares of Relay Therapeutics in a research report on Tuesday. JonesTrading began coverage on shares of Relay Therapeutics in a report on Tuesday, April 14th. They set a &#34;hold&#34; rating and a $18.00 price objective on the stock. Oppenheimer boosted their price objective on shares of Relay Therapeutics from $14.00 to $18.00 and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, April 28th. Wall Street Zen lowered Relay Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, May 9th. Finally, Guggenheim lifted their price target on Relay Therapeutics from $15.00 to $22.00 and gave the company a &#34;buy&#34; rating in a report on Friday, March 13th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Relay Therapeutics has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $22.60.</p>
<div class="lb-trans"><p>多家研究分析师对 RLAY 股票发表了评论。瑞银集团在周二的研究报告中将 Relay Therapeutics 的目标价设定为 26.00 美元。JonesTrading 在 4 月 14 日（星期二）开始覆盖 Relay Therapeutics 的股票。他们对该股票设定了 “持有” 评级和 18.00 美元的目标价。Oppenheimer 在 4 月 28 日（星期二）的研究报告中将 Relay Therapeutics 的目标价从 14.00 美元上调至 18.00 美元，并给予该股票 “跑赢大盘” 评级。华尔街 Zen 在 5 月 9 日（星期六）的报告中将 Relay Therapeutics 的评级从 “持有” 下调至 “卖出”。最后，Guggenheim 在 3 月 13 日（星期五）将 Relay Therapeutics 的目标价从 15.00 美元上调至 22.00 美元，并在报告中给予该公司 “买入” 评级。一位投资分析师对该股票给予了强烈买入评级，八位分析师给予买入评级，一位分析师给予持有评级，一位分析师给予卖出评级。根据 MarketBeat 的数据，Relay Therapeutics 的共识评级为 “适度买入”，共识目标价为 22.60 美元。</p>
</div><p><strong>Check Out Our Latest Report on Relay Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Relay Therapeutics 的最新报告</strong></p>
</div><h2>Insider Activity at Relay Therapeutics</h2>
<div class="lb-trans"><h2>Relay Therapeutics 的内部活动</h2>
</div><p>In related news, CFO Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $12.86, for a total value of $227,840.62. Following the completion of the sale, the chief financial officer directly owned 195,178 shares in the company, valued at $2,509,989.08. The trade was a 8.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold a total of 40,449 shares of company stock worth $532,889 in the last 90 days. Company insiders own 5.04% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Thomas Catinazzo 于 5 月 14 日（星期四）出售了 17,717 股 Relay Therapeutics 股票。该股票以平均价格 12.86 美元出售，总价值为 227,840.62 美元。出售完成后，首席财务官直接持有该公司 195,178 股股票，价值为 2,509,989.08 美元。此次交易使其持股减少了 8.32%。该交易已在与美国证券交易委员会的法律文件中披露，相关文件可通过美国证券交易委员会网站获取。在过去 90 天内，公司内部人士共出售了 40,449 股股票，价值 532,889 美元。公司内部人士持有公司股票的 5.04%。</p>
</div><h2>Hedge Funds Weigh In On Relay Therapeutics</h2>
<div class="lb-trans"><h2>对 Relay Therapeutics 的对冲基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of RLAY. Torren Management LLC purchased a new stake in Relay Therapeutics during the 4th quarter worth approximately $30,000. KBC Group NV acquired a new stake in shares of Relay Therapeutics during the first quarter worth $34,000. Smartleaf Asset Management LLC lifted its stake in shares of Relay Therapeutics by 288.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company's stock worth $37,000 after buying an additional 3,287 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Relay Therapeutics during the fourth quarter valued at $46,000. Finally, Captrust Financial Advisors purchased a new stake in shares of Relay Therapeutics during the second quarter valued at $49,000. 96.98% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近修改了对 RLAY 的持股。Torren Management LLC 在第四季度购买了 Relay Therapeutics 的新股份，价值约 30,000 美元。KBC Group NV 在第一季度收购了 Relay Therapeutics 的新股份，价值 34,000 美元。Smartleaf Asset Management LLC 在第四季度将其在 Relay Therapeutics 的股份增加了 288.6%。Smartleaf Asset Management LLC 现在拥有该公司 4,426 股股票，价值 37,000 美元，此前在此期间又购买了 3,287 股。Caitong International Asset Management Co. Ltd 在第四季度购买了 Relay Therapeutics 的新股份，价值 46,000 美元。最后，Captrust Financial Advisors 在第二季度购买了 Relay Therapeutics 的新股份，价值 49,000 美元。96.98% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Relay Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Relay Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.</p>
<div class="lb-trans"><p>Relay Therapeutics, Inc 是一家临床阶段的生物技术公司，专注于发现和开发精准治疗肿瘤的疗法。公司总部位于马萨诸塞州剑桥，成立于 2016 年，旨在利用综合科学平台针对动态蛋白质运动。Relay Therapeutics 利用计算建模、结构生物学和实验验证来识别能够调节与疾病相关的蛋白质行为的小分子药物候选者。</p>
</div><p>The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.</p>
<div class="lb-trans"><p>公司的核心业务活动集中在其专有的药物发现引擎上，该引擎结合了高性能计算（包括分子动力学模拟）与先进的实验技术，如冷冻电子显微镜和生物物理筛选。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Relay Therapeutics</li>
<li>Tesla Ends Model S and X Era, Bets Everything on What's Next</li>
<li>Why AST SpaceMobile Is the Bigger Winner of the AT&amp;T, T-Mobile, and Verizon Joint Venture</li>
<li>Strategy Inc. Buys Bitcoin and Eyes a Dividend Amid Market Fear</li>
<li>Vertical Aerospace: Pre-Flight Checks Point to a Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Relay Therapeutics 更好的股票</li>
<li>特斯拉结束 Model S 和 X 时代，全力押注未来</li>
<li>为什么 AST SpaceMobile 是 AT&amp;T、T-Mobile 和 Verizon 联合企业的更大赢家</li>
<li>Strategy Inc. 在市场恐慌中购买比特币并关注分红</li>
<li>Vertical Aerospace：飞行前检查指向突破</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Relay Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Relay Therapeutics 吗？</h2>
</div><p>Before you consider Relay Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Relay Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relay Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Relay Therapeutics 并不在名单上。</p>
</div><p>While Relay Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Relay Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Relay Therapeutics 期权交易量异常大（NASDAQ:RLAY）